---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-000369"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2022-01-20T23:59:59+00:00"
generated_at: "2026-06-27T16:52:04.882546+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA clears IND for Compass Therapeutics' CTX-009 Phase 2 study in biliary tract cancers

## Summary
- FDA cleared IND for CTX-009 bispecific antibody targeting DLL4 and VEGF-A.
- Enables global Phase 2 trial in advanced biliary tract cancers including cholangiocarcinoma.
- Will expand ongoing South Korean Phase 2; US clinical sites expected to open in Q2 2022.
- CEO Thomas Schuetz noted CTX-009 has potential as important new therapy for BTC patients.

## SEC filing metadata
- accession: 0001171843-22-000369
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2022-01-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184322000369/0001171843-22-000369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184322000369/f8k_012022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-000369
- JSON: https://secwatch.observer/filing/0001171843-22-000369.json
- Plain text: https://secwatch.observer/filing/0001171843-22-000369.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.